Last updated on July 2020

Comparison FOLFIRINOX Panitumumab vs mFOLFOX6 Panitumumab in RAS/B-RAF Wild-type Metastatic Colorectal Cancer Patients


Brief description of study

National trial, multicenter, randomized, phase II assessing FOLFIRINOX + Panitumumab versus mFOLFOX6 + Panitumumab in metastatic colorectal cancer patients selected by RAS and B-RAF status from circulating DNA analysis.

Evaluation of complete response rate on treatment combining FOLFIRINOX and panitumumab.

Detailed Study Description

PRIMARY OBJECTIVE: Evaluation of complete response rate on treatment combining FOLFIRINOX and panitumumab

SECONDARY OBJECTIVE(S):

  • Overall Survival
  • Progression free survival
  • Secondary resection
  • Early tumor shrinkage (ETS)
  • Depth of response (DpR)
  • Safety profile (NCI CTCAE v 4.03 classification)
  • Diagnostic performance of ccfDNA analysis compared to the tumor-tissue analysis (current gold standard)

Clinical Study Identifier: NCT02980510

Find a site near you

Start Over

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Volunteer Sign-up

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.